Nanobiotix S.A. (NBTX) vs Nuvation Bio (NUVB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Nanobiotix S.A. (NBTX) has outperformed Nuvation Bio (NUVB) over the past year, gaining 26.6% versus a loss of 45.6%. Over five years, NBTX leads with a +214.0% price change compared with -53.5% for NUVB. Nanobiotix S.A. is the larger company by market cap ($1.35 billion vs $1.34 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NBTX | NUVB |
|---|---|---|
| Share price | $26.50 | $3.80 |
| Market cap | $1.35B | $1.34B |
| 1-day change | -2.98% | -0.26% |
| YTD return | +14.62% | -57.59% |
| 1-year return | +26.61% | -45.64% |
| 5-year return | +213.98% | -53.49% |
| EPS (TTM) | $-1.27 | $-0.39 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $62.90M |
| Revenue growth (YoY) | — | +698.96% |
| Net income (latest FY) | — | $-204.63M |
| Operating margin | — | -338.72% |
| Net margin | — | -325.31% |
| 52-week high | $57.14 | $9.75 |
| 52-week low | $19.14 | $3.71 |
| Distance from 52-week high | -53.62% | -61.03% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +101.06% | +227.63% |
| Average volume | 148.94K | 5.24M |
| Shares outstanding | 50.95M | 352.02M |
| Employees | 98 | 310 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NBTX has outperformed NUVB by 72.2 percentage points over the past year.
About Nanobiotix S.A.
NBTX stock →Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs.
Health Care · Biotechnology: Pharmaceutical Preparations · 98 employees
About Nuvation Bio
NUVB stock →Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 310 employees
NBTX vs NUVB FAQ
Which is bigger, Nanobiotix S.A. or Nuvation Bio?
Nanobiotix S.A. (NBTX) is larger, with a market capitalization of $1.35B compared with $1.34B for Nuvation Bio (NUVB).
Which stock has performed better over the past year, NBTX or NUVB?
NBTX returned +26.61% over the past 12 months, compared with -45.64% for NUVB (price return, excluding dividends). Past performance does not predict future results.
Are Nanobiotix S.A. and Nuvation Bio in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.